HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Talent Hunt: Better To Recruit From Academia Than Industry?

This article was originally published in The Rose Sheet

Executive Summary

CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention. In addition to having fewer staff than needed to complete its work, FDA’s hiring problem makes it difficult for the agency to stay abreast of new scientific discoveries and technology.

You may also be interested in...



FDA Personnel Growth Looks To Have Plateaued For Drugs Program

Only a handful of new FTEs are requested in President Obama’s FY 2016 budget request for human drugs activities, suggesting that GDUFA and other related programs may have reached their critical mass of employees for now.

Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting

FDA’s drug center continues to operate with a staffing shortage at a time of tremendous pressure to implement new authorities, with Director Janet Woodcock scrambling to find senior managers to lead top initiatives. Direct hiring authority has helped but doesn’t fully address FDA’s recruiting challenges: too much red tape and too little money.

FDA Generics Director’s Departure Shows Why Chemistry Matters

Another outside candidate is expected to eventually take over for the departing director Gregory Geba, and while the Office of Generic Drugs can run smoothly without a permanent leader for now, it cannot do so forever.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel